<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Enfortumab vedotin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Enfortumab vedotin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Enfortumab vedotin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="126408" href="/d/html/126408.html" rel="external">see "Enfortumab vedotin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F56008753"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Enfortumab vedotin can cause severe and fatal cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later. Closely monitor patients for skin reactions. Immediately withhold enfortumab vedotin and consider referral for specialized care for suspected SJS or TEN, or severe skin reactions. Permanently discontinue enfortumab vedotin in patients with confirmed SJS or TEN, or grade 4 or recurrent grade 3 skin reactions<b>.</b></p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53965332"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Padcev</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56591826"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Padcev</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53952371"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-Nectin-4;</li>
<li>
                        Antineoplastic Agent, Antibody Drug Conjugate;</li>
<li>
                        Antineoplastic Agent, Antimicrotubular;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F53979002"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Actual body weight (up to the maximum dose of 125 mg for patients ≥100 kg) was used to calculate the dose in the clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36041086','lexi-content-ref-33577729','lexi-content-ref-31356140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36041086','lexi-content-ref-33577729','lexi-content-ref-31356140'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33658721-aac9-4ff4-92c8-3f569d461c88">Urothelial cancer, locally advanced or metastatic, combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer, locally advanced or metastatic, combination therapy:</b>
<b>IV:</b> 1.25 mg/kg (maximum dose: 125 mg) on days 1 and 8 of a 21-day cycle (in combination with pembrolizumab); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36041086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36041086'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="333f0d5d-69f9-4e2a-934a-5b8d80a666f6">Urothelial cancer, locally advanced or metastatic, single-agent treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer, locally advanced or metastatic, single-agent treatment:</b>
<b>IV:</b> 1.25 mg/kg (maximum dose: 125 mg) on days 1, 8, and 15 of a 28-day cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33577729','lexi-content-ref-31356140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33577729','lexi-content-ref-31356140'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53979004"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, kidney impairment had no clinically significant difference in enfortumab vedotin (antibody drug conjugate or monomethyl auristatin E) pharmacokinetics. The effect of end-stage kidney disease (with or without dialysis) is unknown.</p></div>
<div class="block doha drugH1Div" id="F53979005"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin 1 to 1.5 times ULN and any AST, or total bilirubin ≤ ULN and AST &gt; ULN): There are no dosage adjustments provided in the manufacturer’s labeling; however, mild impairment had no clinically significant difference in enfortumab vedotin (antibody drug conjugate or monomethyl auristatin E) pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (total bilirubin &gt;1.5 times ULN and any AST): Avoid enfortumab vedotin use.</p></div>
<div class="block doo drugH1Div" id="F57506818"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note</b>
<b>: </b>Per the manufacturer's labeling, the maximum dose for patients ≥100 kg is 125 mg. Actual body weight (up to the maximum dose of 125 mg) was used to calculate the dose in the clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36041086','lexi-content-ref-33577729','lexi-content-ref-31356140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36041086','lexi-content-ref-33577729','lexi-content-ref-31356140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing ; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F53986018"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption>
<b>Recommended Enfortumab Vedotin Dosage Reduction Levels</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Initial (usual) dose</p></td>
<td align="center">
<p style="text-indent:0em;">1.25 mg/kg up to a maximum of 125 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg/kg up to a maximum of 100 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second dose reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">0.75 mg/kg up to a maximum of 75 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third dosage reduction level</p></td>
<td align="center">
<p style="text-indent:0em;">0.5 mg/kg up to a maximum of 50 mg</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Enfortumab Vedotin Dosage Adjustment for Toxicities</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Enfortumab Vedotin Dose Modification</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>Grade 1 is mild, grade 2 is moderate, grade 3 is severe, and grade 4 is life-threatening.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Hematologic toxicities</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3, or grade 2 thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold enfortumab vedotin until ≤ grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold enfortumab vedotin until ≤ grade 1, then reduce dose by 1 dose level or discontinue treatment.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hyperglycemia</p></td>
<td align="center">
<p style="text-indent:0em;">Blood glucose &gt;250 mg/dL</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold enfortumab vedotin until elevated blood glucose has improved to ≤250 mg/dL, then resume treatment at the same dose level. May require insulin.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Peripheral neuropathy</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold enfortumab vedotin until ≤ grade 1, then resume treatment at the same dose level (if first occurrence). For a recurrence, withhold until ≤ grade 1, then resume treatment with the dose reduced by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or higher</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue enfortumab vedotin.</p></td></tr>
<tr>
<td align="center" rowspan="5">
<p style="text-indent:0em;">Dermatologic toxicity (skin reactions)</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Consider topical corticosteroids and antihistamines as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Suspected Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)</p></td>
<td align="center">
<p style="text-indent:0em;">Immediately withhold enfortumab vedotin; consult specialist to confirm the diagnosis. If not SJS/TEN, refer to grade 2 to 4 skin reactions.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Persistent or recurrent grade 2 skin reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Consider withholding enfortumab vedotin until ≤ grade 1, then resume treatment at the same dose level or reduce dose by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 skin reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold enfortumab vedotin until ≤ grade 1, then resume treatment at the same dose level or reduce dose by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Confirmed SJS or TEN; grade 4 or recurrent grade 3 skin reactions</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue enfortumab vedotin.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Pulmonary toxicity: Pneumonitis/Interstitial lung disease</p></td>
<td align="center">
<p style="text-indent:0em;">Signs/symptoms indicative of pneumonitis/interstitial lung disease</p></td>
<td align="center">
<p style="text-indent:0em;">Evaluate and exclude infectious, neoplastic, and other causes.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold enfortumab vedotin until ≤ grade 1, then resume at the same dose level or consider dose reduction by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or higher</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue enfortumab vedotin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Ocular toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Any</p></td>
<td align="center">
<p style="text-indent:0em;">Consider artificial tears for dry eye prophylaxis and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Ophthalmic topical steroids may be considered (after ophthalmic exam) if clinically indicated. Consider enfortumab vedotin dose interruption or dose reduction for symptomatic ocular disorders.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Other nonhematologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold enfortumab vedotin until ≤ grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue enfortumab vedotin.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F53979003"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55044158"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dermatologic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Skin reactions and <b>skin rash</b> are very common with therapy, particularly <b>maculopapular rash</b> and <b>pruritus</b>. Other reactions include <b>exfoliation of skin</b>, <b>skin photosensitivity</b>, <b>urticaria</b>,<b> vesicular eruption</b>, and <b>xeroderma</b>. Severe skin reactions (grade 3 to 4) have occurred in up to 10% of treated patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235241'])">Ref</a></span>), including symmetrical drug-related intertriginous and flexural exanthema, <b>bullous dermatitis</b>, <b>exfoliative dermatitis</b>, and <b>palmar-plantar erythrodysesthesia</b>. Fatal cases of <b>Stevens-Johnson syndrome </b>(SJS) and <b>toxic epidermal necrolysis </b>(TEN) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34495281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34495281'])">Ref</a></span>). Dermatologic toxicities frequently require therapy interruption, dose reduction, and/or discontinuation. Of patients who experienced rash, nearly two-thirds experienced complete resolution and approximately one-fifth experienced partial improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32542157']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32542157'])">Ref</a></span>). Events occurred at a higher rate when enfortumab vedotin was given concurrently with pembrolizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; Nectin-4 (targeted by enfortumab vedotin and also expressed in skin) disturbance may impair cell-cell adhesion leading to epidermal detachment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33319007','lexi-content-ref-34495281','lexi-content-ref-31356140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33319007','lexi-content-ref-34495281','lexi-content-ref-31356140'])">Ref</a></span>). Alternatively, delivery of monomethyl auristatin E (MMAE), a microtubule disruption agent conjugated to enfortumab vedotin, may be the sole attributable factor for dermatologic toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33747934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33747934'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of severe skin reactions was 0.7 months (range: 0.1 to 6 months). Median time to onset for SJS and TEN was 11 days (range: 9 to 21 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34495281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34495281'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia </b>occurred in patients treated with enfortumab vedotin, including severe (grade 3 or 4) and fatal events; therapy interruption is warranted for blood glucose &gt;250 mg/dL. <b>Diabetic ketoacidosis</b> (DKA) was also observed, including DKA in patients without preexisting diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of hyperglycemia was 0.6 months (range: 0.1 to 20 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher BMI</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher baseline HbA1c (patients with HbA1c ≥8% were excluded from initial trials)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ocular disorders are common in patients treated with enfortumab vedotin. Most ocular events involve the cornea and include <b>keratitis</b>, <b>blepharitis</b>, <b>blurred vision</b>, limbal stem cell deficiency, and other events associated with <b>dry eye syndrome</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of symptomatic ocular disorder was 1.6 months (range: 0 to 19 months).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral neuropathy,</b> predominantly <b>peripheral sensory neuropathy</b>, <b>peripheral motor neuropathy</b>, and <b>asthenia</b>, occurred in nearly half of patients treated with enfortumab vedotin in clinical trials. Peripheral neuropathy was usually low grade and manageable, although grade 3 toxicity was reported in a small percentage of patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31356140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31356140'])">Ref</a></span>). Therapy interruption, dosage reduction, and/or permanent discontinuation may be warranted, depending on the severity. Complete resolution occurred in 14% of patients, and 46% of patients had partial improvement (at the time of their last evaluation). Events occurred at a higher rate when enfortumab vedotin was given concurrently with pembrolizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of grade ≥2 peripheral neuropathy was 4.9 months (range: 0.1 to 20 months).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pneumonitis/interstitial lung disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonitis/interstitial lung disease (ILD) </b>occurred in patients treated with enfortumab vedotin, including severe (grade 3 or 4) and fatal events. Events occurred at a higher rate when enfortumab vedotin was given concurrently with pembrolizumab. Events occurred at a higher rate when enfortumab vedotin was given concurrently with pembrolizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; median time to onset of pneumonitis/ILD was 2.7 months (range: 0.6 to 6 months).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F53974714"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (47% to 53%), maculopapular rash (24%), pruritus (26% to 35%), skin rash (52% to 66%; including symmetrical drug-related intertriginous and flexural exanthema [Keerty 2020]), xeroderma (17% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum phosphate (25% to 39%), decreased serum potassium (16% to 19%), hyperglycemia (10% to 16%), weight loss (16% to 35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (20%), constipation (28%), decreased appetite (40% to 52%), diarrhea (35% to 42%; grades 3/4: 4% to 6%), dysgeusia (26% to 42%), increased serum lipase (11% to 18%), nausea (30% to 45%; grades 3/4: 1% to 3%), vomiting (13% to 18%; grades 3/4: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (20% to 38%; grade 3/4: 6% to 11%), decreased neutrophils (14% to 27%; grade 3/4: 5% to 12%), hemorrhage (17%; grade 3/4: 3%), lymphocytopenia (32% to 43%; grade 3/4: 10% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (48% to 56%; including asthenia), peripheral neuropathy (50% to 58%; grade 3/4: 4% to 8%; including abnormal gait and hypoesthesia), peripheral sensory neuropathy (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (13%), dry eye syndrome (24% to 40%; including limbal stem cell deficiency), ocular toxicity (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (18% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum sodium (7% to 8%), increased serum potassium (8%), increased uric acid (7% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (9% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection (3%), sepsis (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Myasthenia (7%), peripheral motor neuropathy (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3%), pneumonia (5%), pneumonitis (2% to 4%; including interstitial lung disease)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption, contact dermatitis, erythema multiforme, palmar-plantar erythrodysesthesia, pustular rash, skin photosensitivity, stasis dermatitis, urticaria, vesicular eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic ketoacidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis, conjunctivitis, eye irritation, increased lacrimation, keratitis, punctate keratitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous dermatitis (Enescu 2022), dermatitis (vacuolar interface dermatitis with maturation disarray of keratinocytes) (Wu 2019), erythematous rash (Dobry 2021), exfoliation of skin (Enescu 2022), exfoliative dermatitis (Enescu 2022), indurated plaques of the skin (Dobry 2021), pruritic rash (Dobry 2021), Stevens-Johnson syndrome (Francis 2020; Viscuse 2021), toxic epidermal necrolysis (Francis 2020; Viscuse 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (bilateral anterior subcapsular) (Thibodeau 2021)</p></div>
<div class="block coi drugH1Div" id="F53952374"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to enfortumab vedotin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F53978986"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: May be an irritant. Skin and soft tissue reactions secondary to extravasation have been observed after enfortumab vedotin administration, including grade 3 or 4 reactions. A small percentage of patients experienced skin and soft tissue reactions. Extravasation reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2 to 7 days after extravasation and resolved within 1 to 4 weeks of peak. A small percentage of patients also developed extravasation reactions with secondary cellulitis, bullae, or exfoliation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Patients ≥75 years of age experienced higher incidences of fatal adverse reactions with enfortumab vedotin (either as a single agent or in combination with pembrolizumab), compared to patients &lt;75 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: In another antibody drug conjugate also containing monomethyl auristatin E, the incidence of ≥ grade 3 adverse events and fatalities was increased in patients with moderate or severe hepatic impairment (compared to normal hepatic function).</p></div>
<div class="block foc drugH1Div" id="F53965333"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Padcev: enfortumab vedotin-ejfv 20 mg (1 ea); enfortumab vedotin-ejfv 30 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F53965331"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53986101"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Padcev Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $3,304.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $4,957.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56591827"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Padcev: 20 mg (1 ea); 30 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F53979006"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 30 minutes. Do not administer as an IV push or bolus. Do not mix with or administer with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">May be an irritant. Ensure adequate venous access prior to infusion. Monitor infusion site during administration for possible extravasation. If extravasation occurs, stop infusion and monitor for adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">When used in combination with pembrolizumab, on the days that both enfortumab vedotin and pembrolizumab are administered, in the clinical trial, enfortumab vedotin was administered first, followed by pembrolizumab ~30 minutes after completion of enfortumab vedotin on the same day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36041086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36041086'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F53978988"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F53952373"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urothelial cancer, locally advanced or metastatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (as a single agent) of locally advanced or metastatic urothelial cancer in adults who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment (in combination with pembrolizumab) of locally advanced or metastatic urothelial cancer in adults.</p></div>
<div class="block mst drugH1Div" id="F53978981"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Enfortumab vedotin may be confused with brentuximab vedotin, elotuzumab, encorafenib, polatuzumab vedotin, tisotumab vedotin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53978882"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F53978879"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Strong) and P-glycoprotein: May increase the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53978984"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 2 months after the last enfortumab vedotin dose. Patients with partners who can become pregnant should use effective contraception during therapy and for 4 months after the last dose of enfortumab vedotin.</p>
<p style="text-indent:0em;margin-top:2em;">Based on data from animal studies, enfortumab vedotin may impair male fertility.</p></div>
<div class="block pri drugH1Div" id="F53978983"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to enfortumab vedotin may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F53978985"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if enfortumab vedotin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 3 weeks after the last enfortumab vedotin dose.</p></div>
<div class="block mop drugH1Div" id="F53979009"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor CBC with differential, blood glucose (monitor closely in patients with, or at risk for, diabetes mellitus or hyperglycemia), and LFTs. Evaluate pregnancy status prior to use in patients who could become pregnant. Monitor for symptoms of new or worsening peripheral neuropathy, ocular disorders, and/or dermatologic toxicity. Monitor for signs/symptoms of pneumonitis or interstitial lung disease (eg, hypoxia, cough, dyspnea, or interstitial infiltrates); evaluate and exclude infectious, neoplastic, or other causes. Consider ophthalmologic evaluation for ocular symptoms that do not resolve. Monitor infusion site during infusion for possible extravasation; if extravasation occurs, monitor extravasation site for adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F53978991"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Enfortumab vedotin is an antibody drug conjugate (ADC) directed at Nectin-4 (an adhesion protein located on cell surfaces). Nectin-4 is highly expressed in urothelial carcinoma as well as breast, gastric, and lung cancers (Rosenberg 2019). It contains an IgG1 anti-Nectin-4 antibody conjugated to a microtubule-disrupting agent, monomethyl auristatin E (MMAE). MMAE is attached to the antibody via a protease cleavable linker. The ADC binds to Nectin-4 expressing cells to form a complex which is internalized within the cell. Released MMAE binds to the tubules and disrupts the cellular microtubule network, inducing cell cycle arrest and apoptosis of Nectin-4 expressing cells (Rosenberg 2019). In animal models, the combination of enfortumab vedotin with an anti-PD-1 monoclonal antibody resulted in immune function upregulation and increased antitumor activity.</p></div>
<div class="block phk drugH1Div" id="F53978992"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Antibody drug conjugate (ADC): 12.8 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Unconjugated monomethyl auristatin E (MMAE): 68% to 82%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Enfortumab vedotin is expected to undergo catabolism to small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE-related catabolites. Unconjugated MMAE is released from the ADC via proteolytic cleavage and is primarily metabolized by CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ADC: 3.6 days; MMAE: 2.6 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ADC: at the end of the infusion; unconjugated MMAE: At ~2 days after a dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Unconjugated MMAE: Feces: 17%; urine: 6%; primarily as unchanged form (data extrapolated from another ADC product).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: ADC: 0.11 L/hour; Unconjugated MMAE: 2.11 L/hour.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235241">
<a name="34235241"></a>Dobry AS, Virgen CA, Hosking AM, et al. Cutaneous reactions with enfortumab vedotin: A case series and review of the literature. <i>JAAD Case Rep</i>. 2021;14:7-9. doi:10.1016/j.jdcr.2021.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/34235241/pubmed" id="34235241" target="_blank">34235241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35242967">
<a name="35242967"></a>Enescu CD, Artz C, Axelson A. Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma. <i>JAAD Case Rep</i>. 2022;21:140-143. doi:10.1016/j.jdcr.2022.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/35242967/pubmed" id="35242967" target="_blank">35242967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33319007">
<a name="33319007"></a>Francis A, Jimenez A, Sundaresan S, Kelly B. A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis. <i>JAAD Case Rep</i>. 2020;7:57-59. doi:10.1016/j.jdcr.2020.10.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/33319007/pubmed" id="33319007" target="_blank">33319007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36041086">
<a name="36041086"></a>Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. <i>J Clin Oncol</i>. 2023;41(1):22-31. doi:10.1200/JCO.22.01643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/36041086/pubmed" id="36041086" target="_blank">36041086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32542157">
<a name="32542157"></a>Keerty D, Graham L, Haynes E, Hembree TN. Flexural exanthema from enfortumab vedotin. <i>Cureus</i>. 2020;12(5):e8102. Published 2020 May 13. doi:10.7759/cureus.8102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/32542157/pubmed" id="32542157" target="_blank">32542157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.2">
<a name="NIOSH.2"></a>National Institute for Occupational Safety and Health (NIOSH) notice. Centers for Disease Control and Prevention website. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated January 21, 2020. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34495281">
<a name="34495281"></a>Nguyen MN, Reyes M, Jones SC. Postmarketing cases of enfortumab vedotin-associated skin reactions reported as Stevens-Johnson syndrome or toxic epidermal necrolysis. <i>JAMA Dermatol</i>. 2021;e213450. doi:10.1001/jamadermatol.2021.3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/34495281/pubmed" id="34495281" target="_blank">34495281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Padcev.1">
<a name="Padcev.1"></a>Padcev (enfortumab vedotin) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Padcev.2">
<a name="Padcev.2"></a>Padcev (enfortumab vedotin) [product monograph]. Mississauga, Ontario, Canada: Seagen Canada Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33577729">
<a name="33577729"></a>Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. <i>N Engl J Med</i>. 2021;384(12):1125-1135. doi:10.1056/NEJMoa2035807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/33577729/pubmed" id="33577729" target="_blank">33577729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31356140">
<a name="31356140"></a>Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. <i>J Clin Oncol</i>. 2019;37(29):2592-2600. doi:10.1200/JCO.19.01140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/31356140/pubmed" id="31356140" target="_blank">31356140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34629907">
<a name="34629907"></a>Thibodeau A, Nallasamy N. bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. <i>Int Med Case Rep J</i>. 2021;14:707-709. doi:10.2147/IMCRJ.S324394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/34629907/pubmed" id="34629907" target="_blank">34629907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33747934">
<a name="33747934"></a>Viscuse PV, Marques-Piubelli ML, Heberton MM, et al. Case report: Enfortumab vedotin for metastatic urothelial carcinoma: A case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens-Johnson syndrome/toxic epidermal necrolysis to dermal hypersensitivity reaction. <i>Front Oncol</i>. 2021;11:621591. Published March 4, 2021. doi:10.3389/fonc.2021.621591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/33747934/pubmed" id="33747934" target="_blank">33747934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865407">
<a name="30865407"></a>Wu S, Adamson AS. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma. <i>Dermatol Online J</i>. 2019;25(2):13030/qt4j44w7w6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/enfortumab-vedotin-drug-information/abstract-text/30865407/pubmed" id="30865407" target="_blank">30865407</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 126407 Version 73.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
